MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcf.2023.10.017

Медицинская библиотека · Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023

A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA.

Bradbury Jacob D, Chesshyre Emily, Orenti Annalisa, Jung Andreas, Warris Adilia, European Cystic Fibrosis COVID project group

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Aspergillus infection is known to be associated with worse respiratory outcomes in people with CF (pwCF) and is a well-recognised complication of severe SARS-CoV-2 infection. The aim of this observational cross-sectional study was to examine the association of pre-existing Aspergillus infection and/or allergic bronchopulmonary aspergillosis (ABPA) in pwCF and severity of COVID-19.

METHODS

Data on SARS-CoV-2 infections in pwCF from January 2020 to June 2021 were collected by the European Cystic Fibrosis Society Patient Registry. The primary outcome was COVID-19 severity measured by hospitalisation comparing those with Aspergillus infection and/or ABPA in the 12 months preceding COVID-19 and those without.

RESULTS

In total, 1095 pwCF were diagnosed with SARS-CoV-2 and information on pre-existing Aspergillus/ABPA status was available from 807. PwCF and SARS-CoV-2 in the Aspergillus/ABPA group (n = 153), in comparison to the non-Aspergillus/ABPA group (n = 654), were more likely to be hospitalised (adjusted OR 1.79 (1.19 to 2.85); p = 0.005) and their disease course was more likely to be complicated by sepsis (adjusted OR 7.78 (1.78 to 49.43); p = 0.008). The association with hospital admission was no longer significant after excluding patients with ABPA. Secondary analysis comparing pwCF who received antifungal treatment (n = 18), versus those who did not (n = 474) during COVID-19, showed a higher rate of hospitalisation (p < 0.001); intensive care unit admission (p < 0.001), and requirement for invasive ventilation (p < 0.001) in the antifungal treated group.

CONCLUSION

We show that pre-existing Aspergillus/ABPA is associated with increased rates of hospitalisation and sepsis during COVID-19 in pwCF.

Для цитирования: Bradbury Jacob D, Chesshyre Emily, Orenti Annalisa, Jung Andreas, Warris Adilia, European Cystic Fibrosis COVID project group. A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA.. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2023. DOI: 10.1016/j.jcf.2023.10.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.